人工智能平台DaltonTx获得400万英镑种子轮融资，用于开发人工智能驱动的药物发现平台-动脉网

DaltonTx Secures £4 Million Seed Funding to Develop AI-Driven Drug Discovery Platforms

GeneOnline 等信源发布 2025-09-23 16:16



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

DaltonTx, a technology company based in the United Kingdom, has secured £4 million in seed funding to advance its efforts in developing adaptive, AI-driven discovery platforms aimed at transforming drug research and development. The announcement marks the company’s emergence from stealth mode as it seeks to address challenges related to the economics, timelines, and outcomes of pharmaceutical R&D..

英国技术公司 DaltonTx 已获得 400 万英镑的种子资金，以推动其开发适应性强、由人工智能驱动的发现平台，旨在变革药物研发。这一公告标志着该公司脱离隐身模式，致力于解决与制药研发相关的经济性、时间表和成果等挑战。

The financing round will support DaltonTx’s mission to create innovative tools that leverage artificial intelligence for streamlining drug discovery processes. By focusing on adaptive technologies, the company aims to enhance efficiency and reduce costs associated with bringing new treatments to market.

本轮融资将支持 DaltonTx 致力于创建利用人工智能简化药物发现过程的创新工具的使命。通过专注于自适应技术，该公司旨在提高效率并降低将新疗法推向市场的成本。

The investment underscores growing interest in AI applications within the healthcare sector and reflects ongoing efforts to improve methodologies for identifying viable drug candidates..

这项投资突显了医疗保健领域对人工智能应用日益增长的兴趣，并反映了为改进识别可行药物候选物的方法学而做出的持续努力。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: September 23, 2025

日期：2025年9月23日

Poll: Media Coverage Influenced 33% of Participants to Forgo Vaccination

民意调查：媒体报导影响了33%的参与者放弃接种疫苗

Regulatory and Payer Issues Hinder AI Integration in Pharmacy Operations, Experts Say.